Title |
Aptamer-labeled PLGA nanoparticles for targeting cancer cells
|
---|---|
Published in |
Cancer Nanotechnology, January 2012
|
DOI | 10.1007/s12645-011-0024-6 |
Pubmed ID | |
Authors |
Athulya Aravind, Saino Hanna Varghese, Srivani Veeranarayanan, Anila Mathew, Yutaka Nagaoka, Seiki Iwai, Takahiro Fukuda, Takashi Hasumura, Yasuhiko Yoshida, Toru Maekawa, D. Sakthi Kumar |
Abstract |
Cancer is one of the leading causes of death in most parts of the world and is a very serious cause of concern particularly in developing countries. In this work, we prepared and evaluated the aptamer-labeled paclitaxel-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles (Apt-PTX-PLGA NPs) which can ameliorate drug bioavailability and enable accurate drug targeting to cancer cells with controlled drug release for cancer therapy. Paclitaxel-loaded PLGA nanoparticles (PTX-PLGA NPs) were formulated by a single-emulsion/solvent evaporation method and were further surface-functionalized with a chemical cross-linker bis(sulfosuccinimidyl) suberate (BS3) to enable binding of aptamer on to the surface of the nanoparticles. The prepared nanoparticles were characterized by atomic force microscopy, scanning electron microscopy, and X-ray photoelectron spectroscopy. Cytotoxicity studies were carried out using normal human mammary epithelial cells (HMEC cells) and human glial cancer cells (GI-1 cells) by methylthiazolyldiphenyl-tetrazolium bromide assay and Alamar blue assay, which confirmed that PTX-PLGA NPs with aptamer conjugation (Apt-PTX-PLGA NPs) were comparatively non-toxic to HMEC cells while toxic to GI-1 cancer cells. Cellular uptake of PTX-PLGA NPs with and without aptamer conjugation was studied using GI-1 cells and monitored by confocal microscopy and phase contrast microscopy. Our studies demonstrated significant internalization and retention of nanoparticles inside the cells, inducing apoptosis. The preferential accumulation of PTX-PLGA NPs within the cancer cells were also confirmed by flow cytometry-based uptake studies. The results indicated that Apt-PTX-PLGA NPs could be a promising targeted therapeutic delivery vehicle for cancer treatment. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Australia | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
China | 1 | 1% |
Unknown | 73 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 14 | 19% |
Student > Master | 10 | 14% |
Researcher | 9 | 12% |
Student > Bachelor | 5 | 7% |
Other | 3 | 4% |
Other | 10 | 14% |
Unknown | 23 | 31% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 12 | 16% |
Agricultural and Biological Sciences | 11 | 15% |
Chemistry | 7 | 9% |
Pharmacology, Toxicology and Pharmaceutical Science | 5 | 7% |
Medicine and Dentistry | 3 | 4% |
Other | 10 | 14% |
Unknown | 26 | 35% |